Education
About Us
Working with TipRanks
Follow Us
Bioline RX Ltd Sponsored ADR (BLRX)
NASDAQ:BLRX
BLRX Stock Chart & Stats
$2.76
-$0.02(-10.62%)
At close: 4:00 PM EST
$2.76
-$0.02(-10.62%)
Day’s Range― - ―
52-Week Range$2.30 - $7.77
Previous CloseN/A
Volume8.80M
Average Volume (3M)23.61K
Market Cap
$12.67M
Enterprise Value$16.15M
Total Cash (Recent Filing)$25.21M
Total Debt (Recent Filing)$11.38M
Price to Earnings (P/E)―
Beta1.37
Next Earnings
Mar 12, 2026EPS Estimate
-0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding4,351,358
10 Day Avg. Volume24,146
30 Day Avg. Volume23,614
Financial Highlights & Ratios
PEG Ratio0.84
Price to Book (P/B)50.79
Price to Sales (P/S)23.63
P/FCF Ratio-15.56
Enterprise Value/Market Cap1.27
Enterprise Value/Revenue1.27
Enterprise Value/Gross Profit2.50
Enterprise Value/Ebitda3.39
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.46
Revenue Forecast (FY)$2.14M
Bulls Say, Bears Say
Bulls Say
Cash RunwayA multi-quarter cash runway into H1 2027 provides durable financing to advance clinical programs and corporate strategy without immediate dilution. This gives management time to progress GLIX1 and motixafortide trials, pursue partnerships, and vote on JV investments before needing urgent capital.
Joint Venture And Clinical ProgressA JV that shares development costs and grants access to Hemispherian's regulatory expertise materially reduces BioLineRx's development risk and cash burden. The FDA-cleared IND and planned Phase I/IIa in early 2026 offer structural clinical de-risking and a clear pathway to value-driving milestones.
Strengthened IP ProtectionA granted patent with protection through 2040 materially enhances long-term exclusivity for GLIX1 across multiple cancer indications. Strong IP supports sustained R&D investment, partnership negotiations, and potential commercial protection, increasing the strategic moat around the program.
Bears Say
Persistent UnprofitabilitySustained negative net margins indicate BioLineRx is operating at a loss despite revenue growth, reflecting structural profitability issues. Persistent operating losses constrain internal funding for trials, increase reliance on external financing or partnerships, and extend the timeline to self-sustaining operations.
Weak Cash GenerationNegative free cash flow and poor operating cash conversion imply the business cannot yet convert revenue into sustainable cash. Over the medium term this forces dependence on financing inflows, raising dilution and refinancing risks that can limit strategic flexibility and R&D continuity.
High LeverageA debt-to-equity ratio above 1 indicates meaningful leverage that increases fixed obligations and refinancing risk. Combined with negative cash flow and losses, high leverage can constrain discretionary R&D spend, elevate interest burdens, and reduce resilience to funding shocks over the next several quarters.
Bioline RX Ltd Sponsored ADR News
BLRX FAQ
What was Bioline RX Ltd Sponsored ADR’s price range in the past 12 months?
Bioline RX Ltd Sponsored ADR lowest stock price was $2.30 and its highest was $7.77 in the past 12 months.
What is Bioline RX Ltd Sponsored ADR’s market cap?
Bioline RX Ltd Sponsored ADR’s market cap is $12.67M.
When is Bioline RX Ltd Sponsored ADR’s upcoming earnings report date?
Bioline RX Ltd Sponsored ADR’s upcoming earnings report date is Mar 12, 2026 which is in 8 days.
How were Bioline RX Ltd Sponsored ADR’s earnings last quarter?
Bioline RX Ltd Sponsored ADR released its earnings results on Nov 24, 2025. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$0.67 by $0.67.
Is Bioline RX Ltd Sponsored ADR overvalued?
According to Wall Street analysts Bioline RX Ltd Sponsored ADR’s price is currently Overvalued.
Does Bioline RX Ltd Sponsored ADR pay dividends?
Bioline RX Ltd Sponsored ADR does not currently pay dividends.
What is Bioline RX Ltd Sponsored ADR’s EPS estimate?
Bioline RX Ltd Sponsored ADR’s EPS estimate is -0.39.
How many shares outstanding does Bioline RX Ltd Sponsored ADR have?
Bioline RX Ltd Sponsored ADR has 4,351,358 shares outstanding.
What happened to Bioline RX Ltd Sponsored ADR’s price movement after its last earnings report?
Bioline RX Ltd Sponsored ADR reported an EPS of $0 in its last earnings report, beating expectations of -$0.67. Following the earnings report the stock price went up 7.692%.
Which hedge fund is a major shareholder of Bioline RX Ltd Sponsored ADR?
Currently, no hedge funds are holding shares in BLRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bioline RX Ltd Sponsored ADR
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
BLRX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mix of positive developments in R&D ventures and strong financial management, offset by minimal revenue growth and reduced operational expenses. The company's strategic focus on innovative treatments and a solid cash position are promising, but current revenue generation and market penetration remain challenges.View all BLRX earnings summariesTechnical Analysis
Synlogic
―
Moleculin Biotech
―
Citius Pharmaceuticals
―
Chemomab Therapeutics
―
Passage Bio
―
Ownership Overview
―
Insiders
<0.01% Other Institutional Investors
99.99% Public Companies and
Individual Investors